NCT03034460 - Efficacy and Safety of CD5024 1% in Acne Vulgaris | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 25, 2016

Primary Completion Date

November 2, 2016

Study Completion Date

November 2, 2016

Conditions

Acne

Interventions

DRUG

CD5024 1% cream

500 µL on half-face, five days a week during 6 weeks

DRUG

CD5024 cream placebo

500 µL on half-face, five days a week during 6 weeks

DRUG

CD0271/CD1579 gel

500 µL on half-face, five days a week during 6 weeks

DRUG

CD0271/CD1579 gel placebo

500 µL on half-face, five days a week during 6 weeks

Trial Locations (7)

Galderma Investigational Site (# 8060), Windsor

Galderma Investigational site, Montreal

Galderma investigational site, Nantes

Galderma investigational site, Nice

Galderma investigational site, Berlin

Galderma investigational site, Bochum

Galderma investigational site, Münster